References
- Andrade P, Sacristán JA, Rentero ML, Hammen V, Dilla T. The burden of rheumatoid arthritis in Spain. Health Econ Outcome Res Open Access. 2017;3(126):2. doi:10.4172/2471-268X.1000126
- Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care. 2012;18(13 Suppl):S295–S302.23327517
- Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002;4(Suppl 3):S265–S272. doi:10.1186/ar57812110146
- CDC. Rheumatoid arthritis (RA); 2018 Available from: https://www.cdc.gov/arthritis/basics/rheumatoid-arthritis.html. Accessed 5 2018.
- NRAS. The burden of rheumatoid arthritis across Europe: a socioeconomic survey (BRASS); 2017 Available from: https://www.nras.org.uk/data/files/Publications/Surveys%20Reports/UoC_HCD_BRASS%20Summary%20Report%20FINAL.pdf. Accessed 5 2018.
- Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus Placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652–662. doi:10.1056/NEJMoa160834528199814
- Gomez Reino J, Loza E, Andreu JL, et al. [Consensus statement of the Spanish society of rheumatology on risk management of biologic therapy in rheumatic patients]. Reumatol Clin. 2011;7(5):284–298. doi:10.1016/j.reuma.2011.05.00221925444
- Eli Lilly. Data on file: Report and critical review of published RA models; 2016.
- Karnon J, Stahl J, Brennan A, Caro JJ, Mar J, Moller J. Modeling using discrete event simulation: a report of the ISPOR-SMDM modeling good research practices task force-4. Value Health. 2012;15:821–827. doi:10.1016/j.jval.2012.04.01322999131
- Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, et al. Adalimumab, etanercept, infliximab,certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technol Assess 2016;20(35)
- BIOBADASER registry. Sociedad Espanola de Reumatologia; 2017.
- López Bastida J, Oliva J, Antoñanzas F, et al. Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias. Gac Sanit. 2010;24:154–170. doi:10.1016/j.gaceta.2009.07.01119959258
- World Health Organisation. Spanish life tables. Available from: http://apps.who.int/gho/data/view.main.LT62210?lang=en. Accessed 2 2016.
- Michaud K, Vera-Llonch M, Oster G. Mortality risk by functional status and health-related quality of life in patients with rheumatoid arthritis. J Rheumatol. 2012;39(1):54–59. doi:10.3899/jrheum.11049122089466
- Dougados M, van der Heijde D, Chen Y, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. Epub ahead of print, 2 Nov 2016.
- Carlson J, Ogale S, Dejonckheere F, Sullivan SD. Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis Value in Health. 2015;18(2):173–179. doi:10.1016/j.jval.2014.10.013.
- Eli Lilly. Data on file: Patient HAQ trajectory beyond RA-BEAM study (RA-BEYOND); 2018.
- Norton S, Sacker A, Dixey J, Done J, Williams P, Young A. Trajectories of functional limitation in early rheumatoid arthritis and their association with mortality. Rheumatology (Oxford). 2013;52(11):2016–2024. doi:10.1093/rheumatology/ket25323934221
- Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. [Review] Health Technol Assess. 2011;15(14):1–278. doi:10.3310/hta15140
- Hernandez AM, Wailoo AJ, Ara R. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Health. 2012;15(3):550–561. doi:10.1016/j.jval.2011.12.01422583466
- Gisbert R BM. Base de Datos de Costes Sanitarios eSalud. Barcelona: Oblikue Consulting, S.L.; 2017 Available from: http://www.oblikue.com. Accessed 5 2018.
- Base de Datos de medicamentos del Consejo General de Farmacéuticos (Bot PLUS 2.0). Available from: https://botplusweb.portalfarma.com. Accessed 2 2018.
- Real Decreto-ley 8/2010, de 20 de Mayo, por el que se adoptan medidas extraordinarias para la reducción del déficit público. Boletín Oficial Del Estado.2010;126:45070 Available from: http://www.boe.es/boe/dias/2010/05/24/pdfs/BOE-A-2010-8228.pdf. Accessed May 2018.
- Instituto Nacional de Estadistica. Índice de Precios de Consumo. Medias anuales; 2016.
- Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL. ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit. 2002;16:334–343.12113733
- González A, Ivanova Y, Zozaya N, Jiménez M, Hidalgo Á, eds. La introducción de los biosimilares en España. Estimación del ahorro para el Sistema Nacional de Salud. 1st ed. Madrid: Fundación Weber; 2017.